Respiratory Distress Syndrome in Premature Infants
Conditions
Keywords
RDS, Preterm Infants, Surfactant, LISA, INSURE, Analgesia, Stress
Brief summary
This study will compare stress, changes in oxygenation and oxidative damage in preterm infants with respiratory distress syndrome (RDS) randomized to receive or not remifentanil as an analgesic drug during the administration of porcine surfactant (poractant alfa, Curosurf®) through the traditional (INSURE) or the less invasive (LISA) method.
Detailed description
At present, LISA and INSURE are both used for surfactant therapy in infants as comparable methods. However, a clear policy of using analgesics during surfactant therapy is still lacking: some neonatologists use analgesics to reduce stress and pain scores, whereas others do not approve their use due to interference with spontaneous breathing. In this open-label, randomized, phase 4 clinical trial, infants admitted to our neonatal intensive unit care (NICU) will be evaluated according to the selection criteria and then randomized to receive or not remifentanil as an analgesic drug during the administration of porcine surfactant (poractant alfa, Curosurf®) via the INSURE or LISA method: Group-1) LISA-analgesic; Group 2) LISA-no analgesic; Group-3) INSURE-analgesic; Group-4) INSURE-no analgesic. Study patients will be stratified by gestational age at birth: Block A) 23.0-27.6 weeks of gestation; Block B) 28.0-31.6 weeks of gestation. Early caffeine administration will be provided according to our NICU guidelines shortly after birth. Infants with adequate respiratory drive will be stabilized on nasal continuous positive airway pressure (CPAP; 4-8 cm of water) right after birth. Oxygen saturation targets will be 90-94%; moderate degrees of hypercarbia (PaCO2 \< 60 mmHg, provided arterial pH \>7.22) will be tolerated. Conditions mimicking respiratory distress syndrome (RDS; i.e. sepsis, air leaks, aspiration pneumonia, congenital heart disease) will be ruled out. RDS diagnosis will be clinical according to the European Guidelines. Nasal CPAP, bi-level CPAP or nasal intermittent positive pressure ventilation (synchronized or not) will be used at the discretion of the attending physician to stabilize the patients. Intubation criteria according to our NICU guidelines will be: 1. severe acidosis (defined as arterial pH\<7.20 with a partial pressure of carbon dioxide (PaCO2) \> 55 mmHg and partial pressure of oxygen (PaO2) \< 50 mmHg) with a fraction of inspired oxygen (FiO2) \> 0.50; 2. severe apnoea. Enrolled infants will be evaluated from birth to day 7 of the hospital stay.
Interventions
PROCEDUREINSURE
Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
PROCEDURELISA
Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
DRUGAnalgesic, Opioid
Remifentanil (0.5-2 micrograms/kg/dose)
Sponsors
Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
Istituto di Ricerca Pediatrica Città della Speranza
Virgilio Paolo Carnielli
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Participants and data analyst will be masked.
Eligibility
Sex/Gender
ALL
Age
168 Days to 223 Days
Healthy volunteers
No
Inclusion criteria
* gestational age at birth between 168 and 223 days, * respiratory distress syndrome (diagnosed on the basis of clinical and/or radiological grounds) with a fraction of inspired oxygen ≥0.30 (for infants born ≤26 weeks' gestational age) or ≥0.40 (for infants born \>26 weeks' gestational age) to achieve a peripheral oxygen saturation of 90-94% within 24 hours of life and good respiratory drive, * written informed consent.
Exclusion criteria
* major malformations, * late admission (after 24 hours of life), * intubation in the delivery room, * severe birth asphyxia, * prolonged rupture of membranes, * air leaks, * no informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cortisol concentrations | At 1, 3, 6 12, 24 hours after surfactant administration and then daily in the first week at the same time of the day (to avoid circadian variations). | Cortisol concentrations will be assessed in saliva, as salivary cortisol levels have been shown to be useful surrogate markers for plasma cortisol levels in neonates. Saliva samples will be collected using an absorbent swab stick, centrifuged at 4000 rpm for 10 minutes and kept at -80°C until assayed (minimum sample volume 25 µl). Enzyme immunoassay (ELISA kit) will be used. Basal samples will be obtained at the hospital admission and right before surfactant. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Galvanic Skin Responses | At 1, 3, 6 12, 24 hours after surfactant administration and then daily in the first week at the same time of the day (to avoid circadian variations). | An instrumental stress-test device measuring galvanic skin conductance will be used (Pain Monitor, Med-Storm, Norway): three electrodes will be attached to the infant's foot (sole and sides of the ankle); skin conductance is measured in micro Siemens (µS). |
| Heart rate | 6 hours before and after surfactant therapy will be analyzed. | Cardiac monitoring will assess heart rate. Traces will be saved onto a computer with a sampling frequency of 1 Hertz. Average heart rate, periods of tachycardia (\>160 bpm for ≥5 seconds) and bradycardia (\<100 bpm for ≥5 seconds) will be recorded. These parameters may be correlated with stress and hemodynamic instability during the procedures. |
| Brain oxygenation | From the hospital admission to day 7 of the hospital stay. | Brain oxygenation will be assessed by near-infrared spectroscopy (NIRS). |
| Oxygen saturation (SpO2) | From the hospital admission to day 7 of the hospital stay. | High precision oxygenation assessment will be attained by high frequency (1 Hz) sampling of SpO2 data from the cardio monitor to a computer, possibly by using multiple pulse oximeters in the same patient. |
| Markers of oxidative stress | At the hospital admission and at 6 and 12 hours after surfactant therapy. | 8-isoprostane and nitrites/nitrates will be dosed on urine samples. |
Contacts
Primary ContactVirgilio Carnielli, MD, PHD
Backup ContactClementina Rondina, MD
Outcome results
None listed